Howard Mayer
Director/Board Member bij PEPGEN INC.
Profiel
Dr. Howard Mayer, MD, is Executive Vice President-Research & Development bij Ipsen SA, een Onafhankelijk Bestuurder bij Entasis Therapeutics Holdings, Inc. en een Executive VP, Head-Research & Development bij Ipsen Pharmaceuticals, Inc. Hij zetelt in de Raad van Bestuur van Adagio Therapeutics, Inc., Entasis Therapeutics Holdings, Inc. en Melmark Charitable Foundation. Dr. Mayer was voorheen werkzaam als Onafhankelijk Bestuurder bij Genocea Biosciences, Inc., als Chief Medical Officer, Senior VP, Head-R&D bij Shire Plc., als Chief Medical Officer bij EMD Serono, Inc., als Head-Clinical Development & Medical Affairs bij Pfizer Inc., als Director-Infectious Diseases Clinical Research bij Bristol Myers Squibb Co., en als Head-Rare Disease Business Unit, R&D bij Takeda Pharmaceuticals U.S.A., Inc. Hij zat ook in de raad van bestuur van Autism Speaks, Inc. Hij behaalde zijn doctoraal aan de Universiteit van Pennsylvania en zijn doctoraal aan het Albert Einstein College of Medicine, Inc.
Actieve functies van Howard Mayer
| Bedrijven | Functie | Begin |
|---|---|---|
| PEPGEN INC. | Director/Board Member | 15-11-2023 |
Melmark Charitable Foundation
 Melmark Charitable Foundation Investment Trusts/Mutual FundsMiscellaneous Melmark Charitable Foundation manages and coordinates all fundraising efforts throughout the Melmark organization. | Director/Board Member | 01-01-2016 |
Autism Speaks, Inc.
 Autism Speaks, Inc. Miscellaneous Commercial ServicesCommercial Services Autism Speaks, Inc. is an organization dedicated to advocating for individuals with autism spectrum disorder and their families. The non-profit company is based in New York, NY. The company aims to increase understanding and acceptance of people with autism and advance research into better interventions for autism spectrum disorder and related conditions. The company was founded by Robert C. Wright and Keith Andrew Wargo has been the CEO of the company since 2021. | Director/Board Member | 01-01-2011 |
Ipsen Pharmaceuticals, Inc.
 Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ipsen Pharmaceuticals, Inc. provides pharmaceutical products. The private company is based in Morristown, NJ. | Chief Tech/Sci/R&D Officer | 01-01-2019 |
Eerdere bekende functies van Howard Mayer
| Bedrijven | Functie | Einde |
|---|---|---|
| IPSEN | Chief Tech/Sci/R&D Officer | 22-09-2023 |
| Ipsen Biopharmaceuticals, Inc. | Chief Tech/Sci/R&D Officer | 01-09-2023 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Director/Board Member | 01-07-2022 |
| INVIVYD, INC. | Director/Board Member | 24-06-2022 |
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | 03-08-2020 |
Opleiding van Howard Mayer
| University of Pennsylvania | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| IPSEN | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| PEPGEN INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Autism Speaks, Inc.
Autism Speaks, Inc. Miscellaneous Commercial ServicesCommercial Services Autism Speaks, Inc. is an organization dedicated to advocating for individuals with autism spectrum disorder and their families. The non-profit company is based in New York, NY. The company aims to increase understanding and acceptance of people with autism and advance research into better interventions for autism spectrum disorder and related conditions. The company was founded by Robert C. Wright and Keith Andrew Wargo has been the CEO of the company since 2021. | Commercial Services |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ipsen Pharmaceuticals, Inc.
Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ipsen Pharmaceuticals, Inc. provides pharmaceutical products. The private company is based in Morristown, NJ. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Melmark Charitable Foundation
Melmark Charitable Foundation Investment Trusts/Mutual FundsMiscellaneous Melmark Charitable Foundation manages and coordinates all fundraising efforts throughout the Melmark organization. | Miscellaneous |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
